{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:44:04Z","timestamp":1786459444026,"version":"build-2736575974"},"reference-count":47,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,8,15]]},"DOI":"10.2169\/internalmedicine.6082-20","type":"journal-article","created":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T22:07:00Z","timestamp":1619388420000},"page":"2577-2584","source":"Crossref","is-referenced-by-count":14,"title":["Oral Minocycline Therapy Improves Symptoms of Myalgic Encephalomyelitis, Especially in the Initial Disease Stage"],"prefix":"10.2169","volume":"60","author":[{"given":"Kunihisa","family":"Miwa","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Miwa Naika Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Int Med 121: 953-959, 1994.","DOI":"10.7326\/0003-4819-121-12-199412150-00009"},{"key":"2","unstructured":"2. Carruthers BM, van de Sande MI, DeMeirleir KL, et al. Myalgic encephalomyelitis: International consensus criteria. J Int Med 270: 327-338, 2011."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in patients with chronic fatigue syndrome\/myalgic encephalomyelitis: an <sup>11<\/sup>C-(<i>R<\/i>)-PK11195 PET study. J Nucl Med 55: 945-950, 2014.","DOI":"10.2967\/jnumed.113.131045"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kataoka Y, Yamato M, Miyashige Y, Tamura Y, Cui Y. Neuroinflammation in animal models of fatigue. Adv Neuroimm Biol 4: 237-244, 2013.","DOI":"10.3233\/NIB-130073"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yamato M, Kataoka Y. Fatigue sensation following peripheral viral infection is triggered by neuroinflammation: who will answer these questions? Neural Regen Res 10: 203-204, 2015.","DOI":"10.4103\/1673-5374.152369"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Komaroff AL, Cho TA. Role of infection and neurologic dysfunction in chronic fatigue syndrome. Semin Neurol 31: 325-337, 2011.","DOI":"10.1055\/s-0031-1287654"},{"key":"7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1034\/j.1600-0463.2003.1110504.x","volume":"111","author":"GL Nicholson","year":"2003","unstructured":"7. Nicholson GL, Gan R, Haiser J. Multiple co-infections (Mycoplasma, Chlamydia, human herpesvirus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS 111: 557-566, 2003.","journal-title":"Apmis","ISSN":"https:\/\/id.crossref.org\/issn\/0903-4641","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Arashima Y, Kato K, Komiya T, et al. Improvement of chronic nonspecific symptoms by long-term minocycline treatment in Japanese patients with Coxiella burnetti infection considered to have post-Q fever fatigue syndrome. Intern Med 43: 49-54, 2004.","DOI":"10.2169\/internalmedicine.43.49"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Iwakami E, Arashima Y, Kato K, et al. Treatment of chronic fatigue syndrome with antibiotics: Pilot study assessing the involvement of Coxiella burnetti infection. Intern Med 44: 1258-1263, 2005.","DOI":"10.2169\/internalmedicine.44.1258"},{"key":"10","unstructured":"10. Aronson AL. Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 176: 1061-1068, 1980."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Garrido-Mesa N, Zarzuelo A, G\u00e1lvez J. What is behind the non-antibiotic properties of minocycline? Pharmacol Res 67: 18-30, 2013.","DOI":"10.1016\/j.phrs.2012.10.006"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Garrido-Mesa N, Zarzuelo A, G\u00e1lvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 169: 337-352, 2013.","DOI":"10.1111\/bph.12139"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rosenberg GA, Estrada EY, Mobashery S. Effects of synthetic matrix metalloproinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents. Differences in response based on strains and solvents. Brain Res 1133: 186-192, 2007.","DOI":"10.1016\/j.brainres.2006.11.041"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Arvin KL, Han BH, Du Y, Lim S-Z, Paul AM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 52: 54-61, 2002.","DOI":"10.1002\/ana.10242"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lee SM, Yune TY, Kim SJ, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 20: 1017-1027, 2003.","DOI":"10.1089\/089771503770195867"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Suk K. Minocycline suppresses hypoxic activation of rodent microglia in culture. Neurosci Lett 366: 167-171, 2004.","DOI":"10.1016\/j.neulet.2004.05.038"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yrj\u00e4nheikki J, Kein\u00e4nen R, Pellikka M, Hkfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95: 15769-15774, 1998.","DOI":"10.1073\/pnas.95.26.15769"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48: 1393-1401, 2001.","DOI":"10.1227\/00006123-200106000-00051"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but existing hypersensitivity in a rat model of neuropathy. J Paharmacol Exp Ther 306: 624-630, 2003.","DOI":"10.1124\/jpet.103.052407"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mei X-P, Xu H, Ren J, Zhou Y, Zhang H, Xu L-X. Post-injury administration of minocycline: an effective treatment for nerve-injury-induced neuropathic pain. Neurosci Res 70: 305-312, 2011.","DOI":"10.1016\/j.neures.2011.03.012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 3: 744-751, 2004.","DOI":"10.1016\/S1474-4422(04)00937-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostrial dopaminergic neurogeneration in the MPTP model of Parkinson&apos;s disease. Proc Natl Acad Sci USA 98: 14669-14674, 2001.","DOI":"10.1073\/pnas.251341998"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington&apos;s disease: a pilot study. Mov Disord 19: 692-695, 2004.","DOI":"10.1002\/mds.20018"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78, 2002.","DOI":"10.1038\/417074a"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Choi Y, Kim H-S, Shin KY, et al. Minocycline attenuates neuronal Cell death and improves cognitive impairment in Alzhemer&apos;s disease models. Neuropsychopharmacology 32: 2393-2404, 2007.","DOI":"10.1038\/sj.npp.1301377"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leucocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125: 1297-1308, 2002.","DOI":"10.1093\/brain\/awf133"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 97: 1314-1326, 2006.","DOI":"10.1111\/j.1471-4159.2006.03799.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33: 160-172, 1990.","DOI":"10.1007\/978-3-642-86812-2_2"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Miwa K. Variability of postural orthostatic tachycardia in patients with myalgic encephalomyelitis and orthostatic tachycardia. Heart Vessels 31: 1522-1528, 2016.","DOI":"10.1007\/s00380-015-0744-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Miwa K, Inoue Y. Truncal ataxia or disequilibrium is unrecognised cause of orthostatic intolerance in patients with myalgic encephalomyelitis. Int J Clin Prac 71: 2017.","DOI":"10.1111\/ijcp.12967"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Miwa K, Inoue Y. The etiologic relation between disequilibrium and orthostatic intolerance in patients with myalgic encephalomyelitis (chronic fatigue syndrome). J Cardiol 72: 261-264, 2018.","DOI":"10.1016\/j.jjcc.2018.02.010"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Miwa K, Inoue Y. Paradigm shift to disequilibrium in the genesis of orthostatic intolerance in patients with myalgic encephalomyelitis and chronic fatigue syndrome. Int J Cardiol Hypertens 5: 100032, 2020.","DOI":"10.1016\/j.ijchy.2020.100032"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Costigan A, Elliott C, McDonald C, Newton JL. Orthostatic symptoms predict functional capacity in chronic fatigue syndrome: implications for management. QJM 103: 589-595, 2010.","DOI":"10.1093\/qjmed\/hcq094"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Nijs J, Nicholson GL, De Becker P, Coomans D, De Meirleir K. High prevalence of mycoplasma infections among European chronic fatigue syndrome patients. Examination of four mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunol Med Microbiol 34: 209-214, 2002.","DOI":"10.1111\/j.1574-695X.2002.tb00626.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Keijmel SP, Delsing CE, Bleijenberg G, et al. Effectiveness of long-term doxycycline treatment and cognitive behavioral therapy on fatigue severity in patients with Q fever fatigue syndrome (Qure Study): a randomized controlled trial. Clin Inf Dis 64: 998-1005, 2017.","DOI":"10.1093\/cid\/cix013"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Mensah FKF, Bansal AS, Ford B, Cambridge G. Chronic fatigue syndrome and the immune system: where are we now? Neurophysiol Clin 47: 131-138, 2017.","DOI":"10.1016\/j.neucli.2017.02.002"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Cader S, O&apos;Donovan DG, Shepherd C, Chaudhuri A. Neuropathology of post-infectious chronic fatigue syndrome. J Neurol Sci 285: S60-S61, 2009.","DOI":"10.1016\/S0022-510X(09)70274-6"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Maes M, Twisk FNM, Kubera M, Ringel K. Evidence for inflammation and activation of cell-mediated immunity in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS): increased interleukin-1, tumor necrosis factor-\u03b1, PMN-elastase, lysozyme and neopterin. J Affect Disord 136: 933-939, 2012.","DOI":"10.1016\/j.jad.2011.09.004"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Tikka T, Flebich BL, Goldsteins G, Kein\u00e4nen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21: 2580-2588, 2001.","DOI":"10.1523\/JNEUROSCI.21-08-02580.2001"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Yasui M, Yoshimura T, Takeuchi S, et al. A chronic fatigue syndrome model demonstrates mechanical allodynia and muscular hyperalgesia via spinal microglial activation. Glia 62: 1407-1417, 2014.","DOI":"10.1002\/glia.22687"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minomicine, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 8: 713-720, 1975.","DOI":"10.1128\/AAC.8.6.713"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Yrj\u00e4nheikki J, Tikka T, Kein\u00e4nen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96: 13496-13500, 1999.","DOI":"10.1073\/pnas.96.23.13496"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Yong VW, Wells J, Giulian F, Gasha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 3: 744-751, 2004.","DOI":"10.1016\/S1474-4422(04)00937-8"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6: 797-801, 2000.","DOI":"10.1038\/77528"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 315: 61-64, 2001.","DOI":"10.1016\/S0304-3940(01)02324-2"},{"key":"46","unstructured":"46. Yang LP, Zhu XA, Tso MO. Minocycline and sulforaphane inhibited lipopolysaccharide-mediated retinal microglial activation. Mol Vis 13: 1083-1093, 2007."},{"key":"47","unstructured":"47. IOM (Institute of Medicine). Beyond Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: Redefining an Illness. The National Academies (Abstract), Washington DC, 2015."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/16\/60_6082-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T03:40:59Z","timestamp":1629517259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/16\/60_6082-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,15]]},"references-count":47,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6082-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,15]]},"article-number":"6082-20"}}